BOSTON--(BUSINESS WIRE)--The Food Allergy Science Initiative, Inc. (FASI) is thrilled to announce a prestigious Program Project Grant (P01) from the National Institutes of Health’s, National Institute of Allergy and Infectious Diseases (NIAID) to support a multidisciplinary research program focused on the neuroimmunology of food allergies.

波士顿--（商业新闻短讯）--食物过敏科学倡议公司（FASI）非常高兴地宣布，美国国立卫生研究院、美国国家过敏与传染病研究所（NIAID）将提供一项享有盛誉的项目资助（P01），以支持一项专注于食物过敏神经免疫学的多学科研究计划。

FASI will receive $2,339,268 in first-year funding and expects to receive this amount from NIAID annually for five years (a potential maximum of $11.6M), contingent on availability of funds..

FASI将获得2339268美元的第一年资金，并预计在五年内每年从NIAID获得这笔资金（可能最高为1160万美元），具体取决于资金的可用性。。

The investment will support cutting-edge research led by Program Director, Dr. Ruslan Medzhitov at Yale University, Steven Liberles at Harvard Medical School, and Daniel Mucida at Rockefeller University, continuing their collaboration to uncover fundamental mechanisms by which the nervous and immune systems interact to drive the development and progression of food allergies.

这项投资将支持由项目主管、耶鲁大学的Ruslan Medzhitov博士、哈佛医学院的Steven Liberles和洛克菲勒大学的Daniel Mucida领导的前沿研究，继续他们的合作，以揭示神经和免疫系统相互作用的基本机制，从而推动食物过敏的发展和进展。

The collaboration will also integrate a Bioinformatics Core at Rockefeller University led by Thomas Carroll, Ph.D. and a Transgenic Animal Core led by Brad Lowell, M.D., Ph.D. at the Beth Israel Deaconess Medical Center. Dr. Christine Olsen, M.D., FASI Co-Founder and Executive Chair, will serve as FASI’s PI on the research collaboration..

该合作还将整合洛克菲勒大学由托马斯·卡罗尔博士领导的生物信息学核心和贝斯以色列女执事医学中心由布拉德·洛厄尔博士领导的转基因动物核心。FASI联合创始人兼执行主席克里斯汀·奥尔森博士将担任FASI研究合作的PI。。

'It's a tremendous honor to receive this grant from NIAID and to continue to collaborate with the amazing research teams at Harvard Medical School, Rockefeller University and the Beth Israel Deaconess Medical Center to unlock the neuroimmune pathways of food allergies,' said FASI's Scientific Founder, Dr.

FASI的科学创始人Dr。

Ruslan Medzhitov..

鲁斯兰·梅日托夫。

'This transformative P01 grant, coupled with additional philanthropic investment from FASI’s generous donors, catalyzes a giant leap forward in our understanding of food allergies,' said Dr. Carlos Bosques, CEO of FASI. “With the unique expertise of this interdisciplinary team and our effective collaborative model, I’m confident that this work will open the doors to groundbreaking discoveries that will pave the way for the development of transformative therapeutics.'.

FASI首席执行官卡洛斯·博斯克斯（CarlosBosques）博士说，这项变革性的P01赠款，加上FASI慷慨捐赠者的额外慈善投资，催化了我们对食物过敏认识的巨大飞跃。“凭借这个跨学科团队的独特专业知识和我们有效的合作模式，我相信这项工作将为开创性的发现打开大门，为变革疗法的发展铺平道路。”。

“We’re excited that FASI's cross-disciplinary team characterizing characterize the neuroimmune mechanisms underlying debilitating food allergy conditions is receiving this significant investment. The grant bolsters FASI's collaborative research network and solidifies its leadership position in food allergy research,” added Dr.

“我们很高兴FASI的跨学科团队正在接受这项重大投资，该团队致力于表征使食物过敏状况衰弱的神经免疫机制。这笔资金支持了FASI的合作研究网络，巩固了其在食物过敏研究中的领导地位，”Dr。

Christine Olsen of FASI..

FASI的Christine Olsen。。

The NIAID grant described in this press release is award number P01AI179273. The content of this press release is solely the responsibility of FASI and does not necessarily represent the official views of the National Institutes of Health.

本新闻稿中描述的NIAID拨款是奖项编号P01AI179273。本新闻稿的内容完全由FASI负责，不一定代表美国国立卫生研究院的官方观点。